ReviewPharmaceutics2025
Nanodelivery of Bioactive Natural Products: A Targeted Therapeutic Breakthrough for Atherosclerosis.
Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Natural Small Molecules Targeting Mitochondrial Quality Control for the Treatment of Metabolic Diseases: Mechanisms, Novel Formulations, and Translational Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- A narrative review of PCSK9 inhibitors: from evolocumab to novel discoveries.Frontiers in pharmacology · 2026Review
- Targeting the CD47-SIRPα Axis in Atherosclerosis: From Pathogenesis to Therapeutic Implications.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Atherosclerosis (AS), as a major pathogenic factor of cardiovascular diseases, remains a global health challenge due to its multifactorial nature and recalcitrant therapeutic limitations. The inherent multitarget activity of bioactive natural products (BNPs) positions them as ideal complements to conventional therapeutics. While effective in symptom management, BNPs often falter due to two critical drawbacks: insufficient targeting and poor bioavailability. Recent nanoparticle drug delivery systems (NDDSs) offer a transformative solution. This article systematically reviews the research progress on the combination of BNPs such as phenols, terpenes, and alkaloids with NDDS for the treatment of AS. By optimizing pharmacokinetic properties and targeting efficiency, NDDSs effectively address the clinical limitations of BNPs in AS treatment, including low bioavailability and poor solubility. The study analyzes various NDDS design strategies and their mechanisms in intervening AS pathological processes, such as improving drug stability, enhancing targeting, and controlled release. Additionally, it explores natural compounds with potential antioxidant, anti-inflammatory, cell transformation-regulating, and lipid metabolism-modulating effects, offering innovative approaches for AS clinical therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.